SYSTEMIC SCLEROSIS

This early-stage trial tests a treatment called CAR-T cell therapy for people with severe autoimmune diseases that haven't responded to other treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. Only 3 participants will be enr…

This phase 2 trial tests whether injecting stem cells from fat tissue directly into finger ulcers can help them heal in people with scleroderma. The study will compare the stem cell treatment to a placebo in 32 adults who have at least one painful, non-healing finger sore. The go…

This early-stage trial is testing a new treatment called CC-97540, which uses a patient's own immune cells modified to target and destroy faulty immune cells. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not improved with s…

This study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…

This early-stage trial is testing a new treatment made from umbilical cord blood cells, called CD19-BCMA CAR-T cells, in 45 people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially serious side effects with…

This study tests whether combining two immune-suppressing drugs, belimumab and rituximab, can improve skin fibrosis in people with early diffuse systemic sclerosis (a rare autoimmune disease that causes skin hardening). Thirty adults will receive either the drug combo or placebo,…

This early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…

This phase 2 trial tests nemolizumab, an injectable drug, in 162 adults with systemic sclerosis (a disease causing skin hardening and organ damage). The main goal is to see if it reduces skin thickness over 52 weeks compared to a placebo. Researchers will also check lung function…

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…

This study tests whether injecting donor stem cells into the hand can safely help heal painful finger ulcers in people with systemic sclerosis (scleroderma). The trial includes 20 adults whose ulcers did not improve with standard therapy. The main goal is to check for side effect…

This study tests a new treatment that uses specially designed immune cells (AD-PluReceptor-NK cells) combined with a drug called tafasitamab and chemotherapy to control autoimmune diseases like systemic sclerosis, lupus, and lupus nephritis. The study has three parts: first check…

This early-phase study tests an experimental cell therapy called LUCAR-DKS1 in 36 adults whose autoimmune diseases (like lupus) have not responded to standard treatments. The main goals are to check safety and find the right dose. This is not a cure—patients may still need long-t…

This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This study tests a stem cell transplant using the patient's own blood cells to treat severe scleroderma (systemic sclerosis) that hasn't improved with standard drugs. The goal is to see if this high-dose therapy is safe and can stop the disease from getting worse. The trial enrol…

This early study tests an injection called EVM18001 in 12 people with active, hard-to-treat lupus, scleroderma, or myasthenia gravis. The main goal is to check safety and find the right dose. Researchers will also look at how the drug works in the body and if it helps control the…

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This study tests a new treatment using a patient's own immune cells, modified to target and attack harmful cells in three severe autoimmune diseases: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single inf…

This study tests whether a stem cell transplant using the patient's own cells can help young people (ages 8 to 25) with life-threatening lupus or scleroderma. The goal is to wipe out the faulty immune system and allow a new, healthy one to grow. The trial will track how long pati…

This early-stage study is testing a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The goal is to see if this approach is safe and can control dise…

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This early-stage trial tests a new treatment called AZD0120 for adults with three autoimmune diseases: systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis. AZD0120 is made from a patient's own immune cells, which are modified in a la…

This early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…

This study tests whether combining two drugs (nintedanib and tocilizumab) works better than standard treatments for lung scarring caused by scleroderma. About 86 adults will take the combo or standard therapy for 56 weeks. The main goal is to see if the combo helps preserve lung …

This study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy aims to reset the immune system by targeting and removing faulty B cells. About 72 adults will re…

This early-stage study tests a new treatment called CABA-201 for people with systemic sclerosis (scleroderma), a disease that causes hardening of the skin and can damage organs. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that dr…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This study tests whether a one-time infusion of specially engineered immune cells (CAR T cells) can improve lung function and skin hardening better than current treatments for people with active systemic sclerosis, a rare autoimmune disease. About 92 adults with lung involvement …

This study tests a new treatment for people with lupus, scleroderma, dermatomyositis, or polymyositis. The treatment uses a patient's own immune cells, which are modified in a lab to find and attack faulty B cells that drive the disease. The goal is to control the autoimmune atta…

This study tests whether itacitinib is safe and effective for adults with systemic sclerosis, a disease that causes skin thickening and organ damage. About 74 participants with early or active disease will receive the drug or a placebo for one year. The main goal is to see if it …

This study is testing a new blood test (the HMEC test) to see if it can better identify which patients with thrombotic microangiopathy (TMA) have a specific immune system problem driving their disease. TMA is a severe condition that damages kidneys and the brain. The researchers …

This study tests whether a personalized facial rehabilitation program can help people with systemic sclerosis who have facial tightness and mouth problems. About 60 adults with this rare autoimmune disease will either receive the rehab program or standard care. The goal is to see…

This study aims to collect blood samples and medical data from 3000 people with autoimmune diseases like lupus, scleroderma, and myositis. Researchers will use these samples to identify new biomarkers and better understand the diseases. The goal is to support future research into…

This study aims to better understand systemic sclerosis, a rare disease that causes skin hardening and organ damage. Researchers will analyze skin and blood samples from 40 adults with the condition to see how different cell types interact. The goal is to find new clues that coul…

This study looks at gut bacteria in people with systemic sclerosis (a chronic autoimmune disease) and compares them to healthy volunteers. Researchers will collect stool samples from 60 patients over 7 months and one sample from healthy controls. The goal is to understand how gut…

This study aims to find better ways to detect lung scarring (interstitial lung disease) early in people with connective tissue diseases like scleroderma or rheumatoid arthritis. Researchers will analyze tiny particles in the blood and use AI to examine lung scans from 200 partici…

This registry enrolls pregnant women or those planning pregnancy who have autoimmune diseases like lupus or rheumatoid arthritis. Researchers at Duke University will track health data to find ways to improve outcomes for mothers and babies. The goal is to better understand risk f…

This study is building a large registry and biorepository of 5,000 adults with various rheumatic diseases like rheumatoid arthritis, lupus, and scleroderma. Researchers at Yale University will collect medical data and biological samples over time to better understand these condit…

This study is creating a large database of information from 10,000 people with esophagus problems like GERD, achalasia, and other motility disorders. Researchers will collect data from standard tests to better understand these conditions. The goal is to improve diagnosis and trea…

This study aims to better understand rare forms of inflammatory arthritis, including those linked to other autoimmune diseases or cancer immunotherapy. Researchers will analyze joint tissue samples from 100 adults to compare the immune cells and molecules involved. The goal is to…

This study is creating a large database and biobank from 2200 patients with chronic inflammatory diseases like lupus, multiple sclerosis, and severe asthma. Researchers will track patients over time to identify new markers that can predict disease activity, treatment response, an…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study follows 500 adults with systemic sclerosis (a rare autoimmune disease causing skin and organ hardening) for up to 5 years. Researchers will track how the disease naturally progresses, including complications like lung or kidney problems, and collect blood samples to be…